Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

Chapuis et al.
Journal of Experimental Medicine
Papers
May 2016
Authors and Affiliates
Aude G. Chapuis,1 Sylvia M. Lee,1 John A. Thompson,2 Ilana M. Roberts,1 Kim A. Margolin,2 Shailender Bhatia,2 Heather L. Sloan,1 Ivy Lai,1 Lelecia Wagener,1 Kendall Shibuya,1 Jianhong Cao,1 Jedd D. Wolchok,3 Philip D. Greenberg,1,4 and Cassian Yee1 1Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA 98109, 2Division of Medical Oncology, Department of Medicine, University of Washington Medical, Center/FHCRC/Seattle Cancer Care Alliance, Seattle, WA 98109, 3Ludwig Center, Memorial Sloan-Kettering Cancer Center, New York, NY 100165, 4Department of Immunology, University of Washington School of Medicine, Seattle, WA 9819